COST ANALYSIS OF PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING SUBCUTANEOUS INTERFERON β-1A VERSUS ORAL DISEASE-MODIFYING DRUGS

被引：0
|
作者：
Kozma, C. M. [1 ]
Munschauer, F. E. [2 ]
Phillips, A. L. [2 ]
机构：
[1] CK Consulting Associates LLC, St Helena Isl, SC USA
[2] EMD Serono Inc, Rockland, MA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.220
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND59
引用
收藏
页码：A69 / A69
页数：1
相关论文
共 50 条
  • [21] A DESCRIPTIVE ANALYSIS OF TIME TO FIRST TREATMENT WITH DISEASE-MODIFYING DRUGS (DMDS) IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE SCLEROSIS (MS)
    Phillips, A. L.
    Edwards, N. C.
    Sutherland, S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A291 - A291
  • [22] Predictors of relapses in patients with multiple sclerosis treated with disease-modifying drugs
    Steinman, L.
    Obi-Tabot, E.
    Wang, H.
    Guilhaume, C.
    Sondhi, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S413 - S413
  • [23] HEALTHCARE RESOURCE USE OF PATIENTS NEWLY DIAGNOSED WITH MULTIPLE SCLEROSIS INITIATING ORAL OR SELF-INJECTABLE DISEASE-MODIFYING DRUGS: A LARGE, NATIONWIDE ANALYSIS OF US ELECTRONIC HEALTH RECORD DATA
    Phillips, A. L.
    Corvino, F. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A438 - A438
  • [24] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Trojano, Maria
    Paolicelli, Damiano
    Fuiani, Aurora
    Pellegrini, Fabio
    Iaffaldano, Pietro
    Direnzo, Vita
    D'Onghia, Mariangela
    [J]. NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S225 - S226
  • [25] Monitoring the use of disease-modifying drugs in multiple sclerosis
    Poluzzi, Elisabetta
    Piccinni, Carlo
    Sacripanti, Chiara
    Tola, Maria Rosaria
    D'Alessandro, Roberto
    Montanaro, Nicola
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S33 - S34
  • [26] The Disability Outcomes of Disease-Modifying Drugs in Multiple Sclerosis
    Hader, Walter
    [J]. NEUROLOGY, 2012, 78
  • [27] Multiple Sclerosis Disease-Modifying Drugs in Children and Adolescents
    Bykova O.V.
    Nankina I.A.
    Drozdova I.M.
    Kvasova O.V.
    Batysheva T.T.
    Boiko A.N.
    [J]. Neuroscience and Behavioral Physiology, 2017, 47 (5) : 544 - 552
  • [28] Postmarketing evidence of disease-modifying drugs in multiple sclerosis
    Maria Trojano
    Damiano Paolicelli
    Aurora Fuiani
    Fabio Pellegrini
    Pietro Iaffaldano
    Vita Direnzo
    Mariangela D’Onghia
    [J]. Neurological Sciences, 2008, 29 : 225 - 226
  • [29] Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
    Ng, Huah Shin
    Zhu, Feng
    Kingwell, Elaine
    Yao, Shenzhen
    Ekuma, Okechukwu
    Evans, Charity
    Fisk, John D.
    Marrie, Ruth Ann
    Zhao, Yinshan
    Tremlett, Helen
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (05):
  • [30] Common Pathways of Disease-Modifying Therapies in Patients With Newly Diagnosed Multiple Sclerosis
    Fox, R.
    Mehta, R.
    Pham, T.
    Park, J.
    Wilson, K.
    Bonafede, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 347 - 347
12345